 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Grifols, S.A. (GRFS) is an Spanish specialty biopharmaceutical company.
The firm develops, manufactures, and distributes a range of plasma derivative products primarily in the European Union, Spain, the United States, and Canada.
It specializes in providing infusion solutions, nutrition products, medical devices, and diagnostic instrumentation and reagents for use in hospitals and clinics.
The company operates in four divisions: Bioscience, Diagnostic, Hospital, and Raw Materials and Others.
The Bioscience division manufactures and sells plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. This division offers plasma products, such as IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic division focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, such as analytical instruments and reagents for diagnostics, as well as blood bank products. This division serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital division manufactures and installs products used by and in hospitals comprising parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others division engages in the sale of intermediate pastes and plasma to third parties. The companys products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and a range of other medical conditions.
Shares are heading higher in an upward trading channel. Presently, shares are near the lower boundary of the said channel. Hisher share prices are expected for this stock.
52-Week Trading Range: $25.13 - $43.45
Entry Point: $40.00
Stop Loss: $38.00
Target Price: $44.00
GRFS closed at our stop loss of $38.
